Loading...
In the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), the first-generation antipsychotic perphenazine was as effective as second-generation antipsychotics for psychotic and cognitive symptoms and produced relatively few adverse effects at low but effective doses. However, critics complained that these patients had chronic illness and that perphenazine was seldom used. These criticisms are now addressed by the European First Episode Schizophrenia Trial (EUFEST), which compared haloperidol at a low but effective dose (1–4 mg/day) with four second-generation antipsychotics in 498 patients with schizophreniform disorder or first-episode schizophrenia. This large, multisite, randomized study was funded by a consortium of ph…